Key Market Indicators
New Zealand's antihypertensive medicine sales are on track to remain at $2.2 million by 2026, according to recent forecasts. Since 1998, demand for these medicines has increased by an average of 4% each year. In 2021, New Zealand was ranked 22nd in the world for antihypertensive medicine sales, with Portugal at the top of the list with $2.2 million. Italy, Spain and Australia followed in second, third and fourth place respectively.
